Clarient, Inc.
31 Columbia
Aliso Viejo,
CA 92656
United States - Map
Phone: 949-425-5700
Fax: 949-425-5701
Web Site: http://www.clarientinc.com
| Clarient, Inc. provides oncology diagnostics services to community pathologists, biopharmaceutical companies, and researchers in the United States. It provides various cancer diagnostic and consultative services, including technical laboratory services and professional interpretation, such as reports and analyses through its Internet-based application, PATHSiTE; and commercial services to biopharmaceutical companies and other research organizations, ranging from drug discovery assistance to the development of directed diagnostics through clinical trials. The company also offers hematopathology testing for leukemia and lymphoma. It has collaboration agreements with Natural Selection, Inc. to use its genomic mathematic capability to supplement proteomic mathematic capability to help develop novel cancer markers, as well as with Prediction Sciences, Inc. to commercialize a novel breast cancer test. The company was formerly known as ChromaVision Medical Systems, Inc. and changed its name to Clarient, Inc. in 2005. Clarient was founded in 1993 and is headquartered in Aliso Viejo, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Ronald A. Andrews Jr., 49
Vice Chairman and Chief Exec. Officer |
N/A
| N/A | Dr. Michael J. Pellini MD, MBA, 43
Pres and Chief Operating Officer |
$
453.00K | N/A | Mr. Raymond J. Land C.P.A., 64
Chief Financial Officer, Principal Accounting Officer, Sr. VP and Corp. Sec. |
$
206.00K | N/A | Mr. David J. Daly , 47
Sr. VP of Commercial Operations |
$
322.00K | N/A | Mr. Peter J. Boni , 62
Director, Chief Exec. Officer of Safeguard Scientifics Inc and Pres of Safeguard Scientifics Inc |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.29% Nasdaq 
Profile
